Common carotid artery

Global Percutaneous Transluminal Angioplasty Balloons Catheter Market Report to 2028 - Size, Share, Outlook, and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 26, 2022
Health, Other Health, Neck, Groin, Marketing, Medtronic, Percutaneous, Angioplasty, Brain, CAGR, Region, PTA, Knee, Application, US, Cerebral arteries, Plaque, Wrist, Chameleon, Common carotid artery, Industry, Arm, Atherosclerosis, Medical imaging

The "Percutaneous Transluminal Angioplasty Balloons Catheter Market, by Type, by Material, by Application, by Diameter Size, by End User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Percutaneous Transluminal Angioplasty Balloons Catheter Market, by Type, by Material, by Application, by Diameter Size, by End User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Percutaneous transluminal angioplasty (PTA) is a procedure that opens up blocked peripheral arteries due to plaque build-up (atherosclerosis).
  • A series of x-ray images are taken to clearly view the narrowed artery after the catheter is advanced into the narrowed artery.
  • Increasing launches of angioplasty balloons catheter products in the market by key players are expected to drive the global percutaneous transluminal angioplasty balloons catheter market growth during the forecast period.

Global Carotid and Renal Artery Stents Markets, 2015-2021 & 2022-2030 Featuring Abbott Labs, Boston Scientific, Cardinal Health, Silk Road Medical, Medtronic, Terumo, Cook, Biotronik - ResearchAndMarkets.com

Retrieved on: 
Friday, March 11, 2022
Health, General Health, Stenosis, Renal artery, Forecast model, Investment, Common carotid artery, Strategic planning, FMD, Patient, RAS, Endarterectomy, COVID-19, CMO, Review, ARAS, Pharmaceutical industry

The "Carotid and Renal Artery Stents (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Carotid and Renal Artery Stents (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • Carotid and Renal Artery Stents (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Carotid and Renal Artery Stents market for the year 2020 and beyond.
  • Develop business strategies by understanding the trends shaping and driving Carotid and Renal Artery Stents market.

Doctors Predict Benefits of Ultrasound Enhancing Agents

Retrieved on: 
Friday, October 1, 2021
General Health, Medical Devices, Hospitals, Health, Radiology, Microcirculation, Harvard Medical School, Assistant, Degenerative disease, Queen's University, Heart rate, Diagnosis, Chemistry (relationship), Plaque, Patient, Common carotid artery, Beth Israel Deaconess Medical Center, ICUS, Health, Physician, Mid America Heart Institute, Heart, Echocardiography, Atheroma, UEA, Risk, Liver, Obesity, Laboratory, CEUS, Union of UEA Students, Medical imaging

Doctors today described new ways to predict whether specific patients will benefit from the use of ultrasound enhancing agents (UEAs) to improve the accuracy of their ultrasound scan for diagnosis of heart disease, the number one killer of Americans.

Key Points: 
  • Doctors today described new ways to predict whether specific patients will benefit from the use of ultrasound enhancing agents (UEAs) to improve the accuracy of their ultrasound scan for diagnosis of heart disease, the number one killer of Americans.
  • Dr. Strom also is a member of the board of directors of the International Contrast Ultrasound Society (ICUS).
  • Doctors also were encouraged to use UEAs to enhance ultrasound images of carotid arteries.
  • UEAs (sometimes also known as ultrasound contrast agents) are injected during an ultrasound scan to enhance the resolution of an ultrasound image of the heart and other organ systems.

Doctors Urge Expanded Use of Ultrasound Contrast Agents

Retrieved on: 
Thursday, September 30, 2021
Nursing, Medical Devices, Medical Supplies, Hospitals, Cardiology, Radiology, Health, Pharmaceutical, General Health, Breast, Cardiology, Degenerative disease, MRI, Â, UCA, Allergy, Stroke, Abdomen, FDA, Multimedia, Patient, Time-invariant system, Pathology, Common carotid artery, ICUS, Physician, Health, Gastroenterology, Adult, Heart, Northeast Ohio Medical University, Kidney, UCAS, CEO, University, Kidney failure, Cardiovascular disease, Nebraska Medicine, Prostate, Risk, Liver, Journal, Whole body imaging, Microbubble, Radiology, Pancreas, Safety, University of Nebraska Medical Center, Pelvis, Movement, CEUS, Rush University Medical Center, Google Images, Medical imaging, Medical device

Ultrasound experts today urged the health care community to work to expand utilization of ultrasound contrast agents (UCAs) in order to offer patients broader access to low-cost, safe and reliable diagnostic imaging.

Key Points: 
  • Ultrasound experts today urged the health care community to work to expand utilization of ultrasound contrast agents (UCAs) in order to offer patients broader access to low-cost, safe and reliable diagnostic imaging.
  • Dr. Wilson is a professor of radiology and gastroenterology at the University of Calgary and Co-President of the International Contrast Ultrasound Society (ICUS).
  • UCAs (sometimes also known as ultrasound enhancing agents) are biocompatible imaging agents that are injected during an ultrasound scan to enhance the resolution of an ultrasound image.
  • The International Contrast Ultrasound Society (ICUS) is a grassroots, non-profit medical society dedicated to advancing the safe and appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care.

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Retrieved on: 
Thursday, January 14, 2021
Angiology, Medical specialties, Cardiovascular system, Vascular diseases, Carotid artery stenosis, Neurosurgery, Vascular surgery, Stenosis, Common carotid artery, Stroke, Carotid ultrasonography, Carotid stenting

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Retrieved on: 
Thursday, January 14, 2021
Health, Technology, Hospitals, Other Health, Telecommunications, Mobile, Wireless, Software, Medical specialties, Angiology, Cardiovascular system, Vascular diseases, Carotid artery stenosis, Stroke, Neurosurgery, Vascular surgery, Stenosis, Common carotid artery, Carotid ultrasonography, Carotid stenting

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

Global Carotid Stents Industry

Retrieved on: 
Wednesday, October 21, 2020
Interventional radiology, Stent, Common carotid artery, Branches of biology

Table 13: Carotid Stents Market in Europe: A Historic Market

Key Points: 
  • Table 13: Carotid Stents Market in Europe: A Historic Market
    Table 15: Carotid Stents Market in France: Estimates and
    Table 17: Carotid Stents Market in Germany: Recent Past,
    Table 21: United Kingdom Market for Carotid Stents: Annual
    Table 22: Carotid Stents Market in the United Kingdom: Historic
    Table 26: Carotid Stents Market in Russia: A Historic Review in
    Forecasts in US$ Thousand by Region/Country: 2020-2027
    Table 30: Carotid Stents Market in Asia-Pacific: Historic
    Table 32: Carotid Stents Market in Australia: Recent Past,
    Table 36: Carotid Stents Market in South Korea: Recent Past,
    Table 38: Rest of Asia-Pacific Market for Carotid Stents:
    Table 39: Carotid Stents Market in Rest of Asia-Pacific:
    Breakdown of Sales by Region/Country: 2012, 2020, and 2027
    Table 44: Carotid Stents Market in Argentina in US$ Thousand:
    Table 45: Carotid Stents Market in Brazil: Estimates and
    Table 47: Carotid Stents Market in Mexico: Recent Past, Current
    and Projections in US$ Thousand: 2020 to 2027
    Table 50: Carotid Stents Market in Rest of Latin America:
    Forecasts in US$ Thousand by Region/Country: 2020-2027
    Table 54: Iranian Market for Carotid Stents: Annual Sales
    Table 55: Carotid Stents Market in Iran: Historic Sales
    Table 57: Carotid Stents Market in Israel in US$ Thousand:
    Table 60: Carotid Stents Market in the United Arab Emirates:
    Table 62: Carotid Stents Market in Rest of Middle East: Recent
    Table 65: Carotid Stents Market in Africa: A Historic Review in

Compelling Outcomes with TCAR vs. CEA in Patients with Carotid Artery Stenosis Published in the Annals of Surgery

Angiology, TCAR, Medical specialties, Anatomy, Vascular diseases, Carotid artery stenosis, Common carotid artery, Stroke, Artery disease, Carotid artery, Neurosurgery, Vascular surgery

These promising outcomes will likely increase the role of TCAR in the management of carotid artery stenosis.

Key Points: 
  • These promising outcomes will likely increase the role of TCAR in the management of carotid artery stenosis.
  • The study evaluated patients who underwent carotid procedures between 2016 and 2019, with 6,384 patients in each group analyzed using propensity score matching.
  • Additionally, there were no statistical differences noted between TCAR and CEA for in-hospital stroke/death (TCAR, 1.6%; CEA, 1.6%, p=0.945) as well as stroke (TCAR, 1.4%; CEA, 1.4%, p=0.881) and death (TCAR, 0.4%; CEA, 0.3%, p=0.662).
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).

InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil

Retrieved on: 
Thursday, July 23, 2020
Medical specialties, Angiology, Cardiovascular system, Interventional radiology, Vascular diseases, Carotid artery, Stent, Common carotid artery, Artery disease, Carotid stenting

Regulatory approval of CGuard EPS in Brazil reflects not only the ANVISA'S recognition of CGuards differentiating features versus conventional carotid stents, but also the need for safer treatments for carotid artery disease.

Key Points: 
  • Regulatory approval of CGuard EPS in Brazil reflects not only the ANVISA'S recognition of CGuards differentiating features versus conventional carotid stents, but also the need for safer treatments for carotid artery disease.
  • Brazil ranks as the sixthlargest populated country in world and the largest healthcare market in Latin America.
  • With a population over 213 million, Brazil represents an important step toward expanding commercial availability of InspireMD products into new territories.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

Results Demonstrating Favorable Outcomes with TCAR vs. TF-CAS in Patients with Carotid Artery Stenosis Published in the Journal of the American Medical Association (JAMA)

Angiology, Cardiovascular system, Circulatory system, Vascular diseases, Carotid artery stenosis, Transports en Commun de l'Agglomération Rouennaise, Carotid artery, Common carotid artery

I am confident that the growing evidence base coupled with publication of these data in JAMA, a peer-reviewed journal, will incrementally drive TCAR towards standard of care.

Key Points: 
  • I am confident that the growing evidence base coupled with publication of these data in JAMA, a peer-reviewed journal, will incrementally drive TCAR towards standard of care.
  • The study evaluated patients who underwent carotid procedures between 2016 and 2019, with 5,251 patients receiving TCAR compared to 6,640 patients receiving TF-CAS, with 3,286 patients in each group analyzed using propensity score matching.
  • Additionally, there were no statistical differences noted between TCAR and TF-CAS for in-hospital myocardial infarction (TCAR, 0.2%; TF-CAS, 0.3%, p=0.47).
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).